1 ,2 About the REDEFINE 1 trial REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg), cagrilintide 2.4 mg monotherapy and semaglutide 2.4 mg monotherapy versus placebo in 3,417 adults with obesity (BMI 30 kg/m 2 ), or overweight (BMI 27 kg/m 2 ) with one or more obesity-related comorbidities, and without type 2 diabetes
(2025, March 02)
A food-effect study carried out in healthy volunteers ( N = 78) reported that individuals receiving once-daily oral semaglutide in the fasting state ( n = 26) had measurable exposure, whereas this was not the case in the fed state where exposure was either limited (11 of 25 individuals) or not observed (14 out of 25 individuals) [25, 28]
10.1016/j.cmet.2017.10.015 109 HengB.LimC
The ubiquitous and abundant tripeptide is synthesized through two sequential, ATP-dependent reactions 3
10 The HOPE trial randomised 121 breast cancer survivors with AI-related arthralgia to a year-long exercise programme of aerobic activity plus supervised strength training, or usual care